|
|
Post by greg on Jan 6, 2016 13:01:32 GMT -5
There's been a lot of discussion about Afrezza being priced too high and having to be lowered. Is Afrezza really priced at a premium to novolog and humalog?? I just checked prices in my neck of the woods and Afrezza is much cheaper at around $285 for a month's supply versus $350 to $450 for the competitors.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 6, 2016 13:04:30 GMT -5
There's been a lot of discussion about Afrezza being priced too high and having to be lowered. Is Afrezza really priced at a premium to novolog and humalog?? I just checked prices in my neck of the woods and Afrezza is much cheaper at around $285 for a month's supply versus $350 to $450 for the competitors. dont need a seperate thread. Thats cash price Insurance pricing is different - as in what payers will have to pay to Sanofi |
|
|
|
Post by greg on Jan 6, 2016 13:09:23 GMT -5
Okay, so what do insurers pay Sanofi for Afrezza. And same question for novolog and humalog. Can anyone provide concrete answers so we all know where we are when discussing lowering prices?
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 6, 2016 13:11:37 GMT -5
Okay, so what do insurers pay Sanofi for Afrezza. And same question for novolog and humalog. Can anyone provide concrete answers so we all know where we are when discussing lowering prices? i think no one here would know that and is confidential between payer and manufacturer/marketing co |
|
|
|
Post by greg on Jan 6, 2016 13:13:47 GMT -5
Okay, so what do insurers pay Sanofi for Afrezza. And same question for novolog and humalog. Can anyone provide concrete answers so we all know where we are when discussing lowering prices? i think no one here would know that and is confidential between payer and manufacturer/marketing co I hope you're wrong, or else we've all been venting about SNY pricing Afrezza out of the market without knowing the facts. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 6, 2016 13:17:40 GMT -5
i think no one here would know that and is confidential between payer and manufacturer/marketing co I hope you're wrong, or else we've all been venting about SNY pricing Afrezza out of the market without knowing the facts. Insurance companies tier drugs based on cost.. So if pricing is right, it should have gone to tier 2. So we know that much to vent that afrezza is priced premium and if priced below injectables, , watch Afrezza in tier 2 faster than you think. |
|
|
|
Post by greg on Jan 6, 2016 13:26:14 GMT -5
I hope you're wrong, or else we've all been venting about SNY pricing Afrezza out of the market without knowing the facts. Insurance companies tier drugs based on cost.. So if pricing is right, it should have gone to tier 2. So we know that much to vent that afrezza is priced premium and if priced below injectables, , watch Afrezza in tier 2 faster than you think. I appreciate this civil back and forth. Just one more question, if I may... In terms of tiering, aren't there any other variables, besides just price? |
|
|
|
Post by tripoley on Jan 6, 2016 13:26:21 GMT -5
There's been a lot of discussion about Afrezza being priced too high and having to be lowered. Is Afrezza really priced at a premium to novolog and humalog?? I just checked prices in my neck of the woods and Afrezza is much cheaper at around $285 for a month's supply versus $350 to $450 for the competitors. The 4 unit (30) and 8 unit (60) costs $285. That's $285/600u = $0.475/unit. Novolog pen is $465/1500u = $0.31/unit. That's retail pharmacy prices. |
|
|
|
Post by mnholdem on Jan 6, 2016 13:37:12 GMT -5
So tripoley's numbers equate to Afrezza needing to retail @ $186 to be competitive. That works on my calculator $186/600u=$0.31/unit.
From $285 to $186 - wow - that really shows how out there Sanofi was in pricing Afrezza
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 6, 2016 13:40:54 GMT -5
Insurance companies tier drugs based on cost.. So if pricing is right, it should have gone to tier 2. So we know that much to vent that afrezza is priced premium and if priced below injectables, , watch Afrezza in tier 2 faster than you think. I appreciate this civil back and forth. Just one more question, if I may... In terms of tiering, aren't there any other variables, besides just price? yes get superior label with decrease to non diabetic a1c and no hypos... and improve in general health - cholesterol .retinpathy....etc etc.. MNKD can demand an arm and leg..from payers |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 6, 2016 13:41:47 GMT -5
So tripoley's numbers equate to Afrezza needing to retail @ $186 to be competitive. That works on my calculator $186/600u=$0.31/unit. From $285 to $186 - wow - that really shows how out there Sanofi was in pricing Afrezza they were adding the 35% that they had to share with MNKD I guess... |
|
|
|
Post by compound26 on Jan 6, 2016 13:45:17 GMT -5
I would cut Afrezza price by 50% (i.e., from $285 to $140/150 per box), considering that average Afrezza users probably use more Afrezza unit wise because: (a) Afrezza will be less likely to cause hypo; (b) one can use larger doses and follow-up doses to get tighter control of BG levels: and (c) Matt B has noted that Afrezza will need larger doses for correction of high BG (but not for stopping BG from rising in the first place).
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 6, 2016 13:55:55 GMT -5
I would cut Afrezza price by 50% (i.e., from $285 to $140/150 per box), considering that average Afrezza users probably use more Afrezza unit wise because: (a) Afrezza will be less likely to cause hypo; (b) one can use larger doses and follow-up doses to get tighter control of BG levels: and (c) Matt B has noted that Afrezza will need larger doses for correction of high BG (but not for stopping BG from rising in the first place). i would even say $100... that will get all international afrezza aware diabetics to get on Afrezza... there should be lot of them |
|
|
|
Post by mnholdem on Jan 6, 2016 14:00:05 GMT -5
Any reduction may attract more out-of-pocket payers until it gets coverage.
|
|
|
|
Post by greg on Jan 6, 2016 14:04:41 GMT -5
A good first step for MNKD might be a high-profile slashing of the price, perhaps even announcing it at next week's presentation.
|
|
